16/05/2012 - Workshop Looking for a Win-win in Medical Innovation


16 May 2012

Vrije Universiteit Brussel 
Offices – Marconi zaal - Pleinlaan 9, 2nd floor - 1050 Brussels (right across the street from the VUB campus and M building)

EXCLUSIVE WORKSHOP (max 30 participants)

Medical innovation can be a win-win for all the involved stakeholders: industry, research and development, authorities and patients. What is the contribution of Belgium to innovation with regard to Europe 2020? What is the current situation in Flanders? In Wallonia? What are the strong elements? What are weak elements? Who are the involved actors? What are the financing mechanisms? What are the expected results? What is the expected added value? Can other/new financingmechanisms be linked to it?

Aimed at debate: What are the objectives? What are the EU tendencies? Where does Belgium want to go? What are the boundary conditions and necessary incentives?


14:00 Registration + welcome with coffee

14:30 Introduction by Marleen Wynants (CROSSTALKS)

14:45 Setting the scene by Alain Dupont (VUB)

15:00-15:30 Presentation by Rudy Dekeyser (VIB)

15:30- 16:00 Presentation by Julien Compère (Governement Wallonie)

16:00-16:30 Presentation by Bart Lambrecht (UGent)

16:30-17:30 Debate with Jean Stéphenne (GSK) and Daniel Pipeleers (VUB) - moderated by Alain Dupont (VUB)

17:30 Drinks & networking




Bios / Slides

Rudy Dekeyser is managing director of VIB, a life sciences research institute, based in Flanders, Belgium. VIB performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications.

Julien Compère studied Law and European Law at the Université de Liège and the University of Leicester. He is now Chief of Staff at the Office of Deputy Prime Minister and Minister for Economy, Foreign Trade and Higher Education Jean-Claude Marcourt. He is also Deputy Chairman of the Board at St’art S.A. and member of the Board of Directors at the Centre Hospitalier Universitaire de Liège.

Bart Lambrecht obtained the MD/PhD degree at the University of Ghent, Belgium in 1993 and 1999. After obtaining the MD/PhD degree under the mentorship of Prof. Romain Pauwels, he moved to The Netherlands where he trained in Pulmonary Medicine. He became Professor of Pulmonary Medicine in 2005, holding a special chair in Immunopathology of the Lung at the pulmonary research program of Erasmus University, Rotterdam, The Netherlands. After ten years in The Netherlands, he moved back to Belgium and was appointed Professor of Pulmonary Medicine at Ghent University, and is currently heading a group of 24 scientists dealing with the immunopathology of asthma and immunotherapy of cancer. He is the author of over 100 papers dealing with the use of mouse models to study the pathogenesis of asthma and cancer related immunosuppression.

Jean Stéphenne was appointed Chairman and President, Biologicals at GlaxoSmithKline in 1998. He is a member of the Corporate Executive Team. Stéphenne has overseen Biologicals since 1991, serving as Vice President and General Manager, then Senior Vice President and General Manager, until he was appointed to his current role in 1998. Prior to this, he was Vice President of Human Vaccines Research and Development and Production from 1988 to 1991. Stéphenne joined the company in 1974 as Head of Bacterial and Viral Vaccines production, becoming Vaccine Production Director in 1980. He served in a variety of capacities as Vaccine Plant Director and R&D Director from 1981 to 1991. He received an Engineer in Chemistry and Bio-Industries degree from the University of Gembloux, Belgium, in 1972 and also has a degree in Management from the University of Louvain, Belgium. He has served as President of the Union of French Speaking Companies between 1998 and 2000, is a member of the European Association of Vaccine Producers, and a member of the Management Committee of the Belgian Companies Federation. He is also a member of the Board of several Belgian companies. Stéphenne was named Baron by King Albert II of the Belgians in 2000 in recognition of his leading contribution to R&D and industry in Belgium. Jean served a three year term from June 2008 on the GAVI Alliance Board and its Executive Committee after he was elected by the Vaccine Industry CEOs to be their representative.

Daniel Pipeleers finished his PhD in medical sciences at Vrije Universiteit Brussel in 1976. Since 1980, he is Professor at the Faculty of Medicine of VUB and Director of the Diabetes Research Center. His research and development area is situated in biology and pathology of beta cells and in strategies and the development of beta cell therapy in diabetes.
He owns patents on the isolation and use of insulin-producing beta cells and has written extensively on this topic, holding a publication list featuring over 200 publications.
Until 2000 he was Coordinator of the EU multicenter program on Beta Cell Transplantation and Director of the Interdisciplinary Center of Excellence Juvenile Diabetes Foundation. From 2002 on, he is also Director of the JDRF Center for Beta Cell Therapy in Diabetes and Coordinator of the EU-Integrated Project in 6th Framework. Daniel Pipeleers has been member of various editorial boards, and is associated with many scientific organizations. He is founder (and Chairman of some of them) of the "Belgian Diabetes Registry", the “Beta Cell Bank", the VUB spin-off company Beta Cell and OPUS.

Alain Dupont, MD, PhD, an internist and certified clinical pharmacologist, is full professor and head of the Department of Pharmacology at the Vrije Universiteit Brussel, and head of the department of Clinical Pharmacology and Pharmacotherapy at the University Hospital UZ Brussel, where he also runs a hypertension clinic. He has been Vice-Dean Research and is currently Dean of the Faculty of Medicine and Pharmacy. Dupont is a member and was the founding president of the Belgian Commission for Reimbursement of Medicines. His research activities, mainly in the fields of hypertension and cardio-vascular pharmacology, resulted in 3 prizes, over 120 publications in peer reviewed journals as well as several chapters in books. He chairs the Accompanying Committee of CROSSTALKS.